European Companies Search Engine
EU funding (€5,612,444): Soraprazan - a new regenerative therapy for Stargardt's disease Hor1 Dec 2017 EU Research and Innovation programme "Horizon"
Overview
Text
Soraprazan - a new regenerative therapy for Stargardt's disease
Soraprazan – a new regenerative therapy for Stargardt’s disease Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy or orally taken Soraprazan treatment compared to placebo.
Funded Companies:
| Company name | Funding amount |
| Academisch Ziekenhuis Leiden | €178,223 |
| Eberhard Karls Universitaet Tuebingen | €467,500 |
| Katairo GmbH | €2,705,000 |
| Ospedale SAN Raffaele Srl | €180,171 |
| Smerud Medical Research Germany GmbH | €0.00 |
| Smerud Medical Research International AS | €1,561,250 |
| Smerud Medical Research UK Ltd. | €0.00 |
| Stichting Radboud Universitair Medisch Centrum | €139,519 |
| Universitatsklinikum Bonn | €128,281 |
| University Hospitals Southampton NHS Foundation Trust | €0.00 |
| University of Southampton | €252,500 |
Source: https://cordis.europa.eu/project/id/779317
The filing refers to a past date, and does not necessarily reflect the current state.